L'Oréal Dermatological Beauty Pro is a digital community empowering healthcare professionals to improve their daily practice of dermatology through cutting-edge research, science and education on skin and hair care.
Trichomegaly
- 10min
- May. 2022
- Supported by
Therapeutic classes inducing this adverse event
EGFR inhibitor, MEK inhibitor, Hormone therapy
CTCAE V5.0
Increase in length, thickness or density of hair that the patient is either able to camouflage by periodic shaving or removal of hairs or is not concerned enough about the overgrowth to use any form of hair removal
SIMPLIFIED GRADING
Not obvious, easy to camouflage
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
CTCAE V5.0
Increase in length, thickness or density of hair at least on the usual exposed areas of the body [face (not limited to beard/moustache area) plus/minus arms] that requires frequent shaving or use of destructive means of hair removal to camouflage; associated with psychosocial impact
SIMPLIFIED GRADING
Visible, requires hair removal (shaving, epilation, etc.) to camouflage OR Mechanical eye irritation secondary to trichomegaly OR Psychosocial impact
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
Browse for more adverse events